Scholar Rock Presents New SMA and FSHD Data at Key Neuromuscular Conferences — Scholar Rock Holding Corporation

Event summary

Scholar Rock will present new clinical data at two neuromuscular disease conferences in June 2026.
Presentations include Phase 3 SAPPHIRE trial results and Phase 2 FORGE study updates for SMA and FSHD treatments.
Key presentations feature post-hoc analyses of apitegromab efficacy in nonambulatory SMA patients.
Conferences take place June 24-26 in Orlando (Cure SMA) and June 25-26 in Chicago (FSHD Society).

The big picture

Scholar Rock is positioning itself as a leader in neuromuscular disease treatment through its myostatin biology platform. The company's focus on SMA and expanding into FSHD represents a strategic push into rare disease markets with significant unmet needs. Success in these indications could validate Scholar Rock's approach to muscle-targeted therapies, potentially attracting partnerships or acquisition interest.

What we're watching

Regulatory Pathway: Whether the Phase 3 SAPPHIRE trial data will support apitegromab's regulatory approval for SMA.
Clinical Efficacy: How post-hoc analyses of nonambulatory patients may expand apitegromab's potential patient population.
Pipeline Expansion: The pace at which Scholar Rock can advance its FORGE study for FSHD, a new indication.